恩替卡韦对阿德福韦酯应答不佳患者的疗效分析  

The treatment effectiveness analysis of ETV in the treatment of patients with suboptimal response to ADV

作　　者：陈继林[1] 郭中华[1] 朱珍才 李殊[1] 

机构地区：[1]莲花县人民医院,江西337100

出　　处：《安徽卫生职业技术学院学报》2016年第3期63-64,66,共3页Journal of Anhui Health Vocational & Technical College

摘　　要：目的:研究3种不同治疗方案对阿德福韦酯(ADV)应答不佳患者的临床疗效和安全性。方法:A组应用LAM联合ADV挽救治疗,B组应用ETV治疗,C组应用ETV联合ADV治疗。观察治疗前后患者血清肝功能指标(ALT和AST)、HBe Ag和HBV DNA水平的变化。结果:治疗36、48周后B组和C组肝功能指标改善情况和HBV DNA转阴率明显优于A组(P<0.05);与B组相比,C组肝功能指标,HBe Ag阳性患者阴转率和HBV DNA转阴率均无明显差异。结论:ETV治疗ADV应答不佳的慢性乙型肝炎患者疗效确切。Aim To investigate the efficacy and safety of three different treatment options in patients with suboptimal response to ADV.Methods：A group patients received the combined therapy with LAM and ADV. B group patients received the therapy with ETV. C group patients received the combined therapy with ETV and ADV. The changes in levels of alanine aminotransferase（ ALT）, aspartate aminotransferase （ AST）, HBeAg and HBV DNA before and after treatment, were measured in three groups.Results：The liver function index and serum HBV DNA clearance rates in B and C group were significantly better than those in A group after 36 and 48 weeks of treatment（P〈0.05）.There was no significant difference in the liver function index,HBeAg seroconversion rate and HBV DNA clearance rates between B group and C group.Conclusion：ETV has good therapeutic effect in treating CHB patients with suboptimal response to ADV.

关 键 词：恩替卡韦 阿德福韦酯应答不佳 慢性乙型肝炎 拉米夫定 

分 类 号：R541.61[医药卫生—心血管疾病]